Skip to main content

Table 1 Selected characteristics of the two study groups

From: A Placebo-Controlled Trial of Riboflavin for Enhancement of Ultramarathon Recovery

Characteristic

Riboflavin

(n = 18)

Placebo

(n = 14)

Age (years)

44 ± 8

46 ± 7

Sex (% men)

83

79

Average weekly running distance (km)a

83 ± 20

94 ± 20

Highest week running distance (km)a

135 (126–156)

129 (120–142)

Longest training run or race (km)a

80 (66–92)

80 (56–97)

Body mass change from registration to post-race (%)

−3.6 ± 2.1

−2.6 ± 2.0

Finish time (hours)

27.26 ± 2.36

27.08 ± 2.88

Used any pain medication during the race (%)

50

36

Used any pain medication in 10 days post-race (%)

33

43

Post-race plasma CK (U/L)

6804 (3536–24,592)

12,819 (7560–46,965)

  1. Data are reported as mean ± SD, a percentage, or median (interquartile range) if the data were skewed for either group
  2. aDistances are during the 3 months prior to the race. No significant group differences were present